


AMENDMENT OF THE CLAIMS:

1. (Currently amended) A compound of formula (I):



wherein:

R¹ ~~represents~~ is substituted or unsubstituted heterocyclyl;

Y ~~represents~~ is -(CR_{na}R_{nb})_n-;

R_{na} and R_{nb} are each independently hydrogen or C₁₋₆alkyl;

n is an integer from 1 to 5;

R² ~~represents~~ is unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl;

R³ ~~represents~~ is hydrogen or C₁₋₆alkyl;

and salts and solvates thereof;


with the proviso that the following compound is excluded;

N- {[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-(1,1-dioxidothiomorpholin-4-yl)acetamide.

2. (Original) A compound of formula (I) according to claim 1 wherein R¹ is unsubstituted or substituted pyrandionyl, unsubstituted or substituted uracilyl, unsubstituted or substituted piperidinyl, unsubstituted or substituted hydantoinyl, or unsubstituted or substituted piperazinyl.

3. (Currently amended) A compound of formula (I) according to claim 1 ~~or claim 2~~ wherein R¹ is pyran-3,4-dion-6-yl, 4-methyluracil-6-yl, 1-(methylcarbonyl)piperidin-4-yl, piperidin-4-yl, 1-(aminocarbonyl)piperidin-4-yl, 1-(cyclopropylaminocarbonyl)piperidin-4-yl, 1-(*tert*-butoxycarbonyl)piperidin-4-yl, 4-(methanesulphonylamino)piperidin-1-yl, 4-(methylcarbonylamino)piperidin-1-yl, 1-

(cyclopropylcarbonyl)piperidin-4-yl, 1-(ethylaminocarbonyl)piperidin-4-yl, 1-(*iso*-propylaminocarbonyl)piperidin-4-yl, 1-(*iso*-propylcarbonyl)piperidin-4-yl, 1-(ethoxycarbonyl)piperidin-4-yl, 1-(methoxycarbonyl)piperidin-4-yl, 1-(ethylcarbonyl)piperidin-4-yl, 1-(ethanesulphonyl)piperidin-4-yl, 1-(methylaminocarbonyl)piperidin-4-yl, 1-(methanesulphonyl)piperidin-4-yl, 1-



4. (Currently amended) A compound of formula (I) according to ~~any one of the preceding claims~~ claim 1 wherein R_{na} and R_{nb} are both hydrogen.

5. (Currently amended) A compound of formula (I) according to ~~any one of the preceding claims~~ claim 1 wherein n is 1 or 2.

6. (Currently amended) A compound of formula (I) according to ~~any one of the preceding claims~~ claim 1 wherein R³ is hydrogen.


7. (Currently amended) A compound of formula (I) according to ~~any one of the preceding claims~~ claim 1 wherein R² is unsubstituted or substituted phenyl or unsubstituted or substituted thiophenyl.

8. (Currently amended) A compound of formula (I) according to ~~any one of the preceding claims~~ claim 1 wherein R² is phenyl substituted with chloro.

9. (Currently amended) A compound of formula (I) according to any ~~one of the preceding claims~~ claim 1 wherein R^2 is 3,4-dichlorophenyl.

10. – 13. (Cancelled)

14. (Original) A process for the preparation of a compound of formula (I) as defined in claim 1 which process comprises the reaction of a compound of formula (II) with a compound of formula (III);




wherein;


R^1 , Y, R^3 , and R^2 are as hereinbefore defined for formula (I) in claim 1, in the presence of a base and an activating agent and optionally a peptide coupling agent, and thereafter, if required, carrying out one or more of the following optional steps:

- (i) converting a compound of formula (I) to a further compound of formula (I);
- (ii) removing any necessary protecting group;
- (iii) preparing a salt or solvate of the compound so formed.

15. (Original) A process for the preparation of a compound of formula (I) as defined in claim 1 wherein Y is $-CH_2-$ and R^1 is an unsubstituted or substituted N-linked heterocyclyl group i.e. a compound of formula (XI)




which process comprises the reaction of a compound of formula (XII) with a compound of formula (XIII);



wherein (XII) is an unsubstituted or substituted heterocyclyl group, L^2 is a leaving group, and R^3 and R^2 are as hereinbefore defined for formula (I) in claim 1, and thereafter, if required, carrying out one or more of the following optional steps:


- (i) converting a compound of formula (I) to a further compound of formula (I);
- (ii) removing any necessary protecting group;
- (iii) preparing a salt or solvate of the compound so formed.

16. (Original) A compound of formula (IIIBR)




wherein A is a protected amino group and R^2 is as defined for formula (I) in claim 1.

17. (Original) A compound of formula (IIIBE)



wherein A is a protected amino group and R^2 is as defined for formula (I) in claim 1.

18. (Original) A compound of formula (XIII)



wherein L^2 is a leaving group and R^2 and R^3 are as defined for formula (I) in claim 1.

19. (Original) A compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof for use as an active therapeutic agent.

20. (Currently amended) A compound of formula (I) as defined in claim 1, or a physiologically acceptable salt or solvate thereof, for use in the treatment of inflammatory conditions, ~~e.g. asthma or rhinitis.~~

21. (Currently amended) A method of manufacture of a medicament for the treatment of inflammatory conditions comprising the step of incorporating ~~Use of a~~ compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate ~~thereof for the manufacture of a~~ in said medicament for the treatment of ~~inflammatory conditions, eg. asthma or rhinitis.~~

22. (Currently amended) A method for the treatment of a human or animal subject suffering from or susceptible to an inflammatory condition ~~e.g. asthma or rhinitis,~~ which method comprises administering an effective amount of a compound of

formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof.

23. (Original) A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1, or a physiologically acceptable salt or solvate thereof, and optionally one or more physiologically acceptable diluents or carriers.